Novo Nordisk 'comfortable' with impact of Medicare price negotiations for GLP-1s: CEO
Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...
Novo Nordisk beats on Wegovy sales, expects slower 2025 growth
Danish drugmaker Novo Nordisk (NVO) reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...
hcinnovationgroup3d
How Would the New Administration’s Nominations Impact Obesity Care?
As more research is published about the health benefits associated with GLP-1s, like sleep apnea, heart disease, and ...
health.wusf.usf.edu4d
About half of Americans approve of using weight-loss drugs to treat obesity, a poll finds
The AP-NORC survey shows about half of U.S. adults believe it is a good thing for adults to use Ozempic, Wegovy and similar ...
Hosted on MSN4d
Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?
Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...
News & Record4dOpinion
Froma Harrop: Dems need to focus, starting with drug prices
Donald Trump is executing a shock-and-awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ...
The Columbian5d
Harrop: Democrats should focus, start with drug prices
Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, are quickly slapped down in the courts. Some, ...
Here's why researchers think most people stop taking weight loss drugs within a year
Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...
Sun Journal6d
Froma Harrop: Democrats need to pick and choose: Start with drug prices
Novo Nordisk, maker of Ozempic and Wegovy, has been charging Americans outlandish ... The right-wing argues, as Project 2025 ...